The global Lichen Nitidus Treatment Market was valued at USD 94.93 million in 2016 and is projected to reach USD 200.29 million by 2025, growing at a CAGR of 8.65% from 2017 to 2025.
Increasing prevalence of skin diseases across the globe is the major factor contributing the growth of the market. Unawareness about rare skin diseases among people may act as a restrain for the market growth.
Sample Infographics:
Market Dynamics:
1. Market Drivers
1.1 Increasing prevalence of skin diseases
2. Market Restraints
2.1 Lack of awareness about rare skin diseases
Market Segmentation:
1. Global Lichen Nitidus Treatment Market, by Treatment:
1.1 Corticosteroids
1.2 Retinoid
1.3 Antihistamines
1.4 Others
2. Global Lichen Nitidus Treatment Market, by Type:
2.1 Topical
2.2 Oral
3. Global Lichen Nitidus Treatment Market, by End User:
3.1 Hospitals
3.2 Dermatology Clinics
3.3 Others
4. Global Lichen Nitidus Treatment Market, by Region:
4.1 North America (U.S., Canada, Mexico)
4.2 Europe (Germany, UK, France, Rest of Europe)
4.3 Asia Pacific (China, India, Japan, Rest of Asia Pacific)
4.4 Latin America (Brazil, Argentina, Rest of Latin America)
4.5 Middle East & Africa
Competitive Landscape:
The major players in the market are as follows:
1. Pfizer Inc. (U.S)
2. Novartis AG (Switzerland)
3. Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (U.S)
4. Sanofi (France)
5. GlaxoSmithKline plc. (U.K)
6. AstraZeneca (U.K)
7. Hubei Gedian Humanwell Pharmaceutical Co., Ltd (China)
8. Farmabios SPA (Italy)
9. Horizon Pharma plc. (Ireland)
These major players have adopted various organic as well as inorganic growth strategies such as mergers & acquisitions, new product launches, expansions, agreements, joint ventures, partnerships, and others to strengthen their position in this market.
RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE:
Research study on the Lichen Nitidus Treatment Market was performed in five phases which include Secondary research, Primary research, subject matter expert advice, quality check and final review.
The market data was analyzed and forecasted using market statistical and coherent models. Also market shares and key trends were taken into consideration while making the report. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis.
To know more about the Research Methodology of Verified Market Intelligence and other aspects of the research study, kindly get in touch with our sales team.
1 INTRODUCTION OF GLOBAL LICHEN NITIDUS TREATMENT MARKET
1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions
2 EXECUTIVE SUMMARY
3 RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources
4 GLOBAL LICHEN NITIDUS TREATMENT MARKETOUTLOOK
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework
5 GLOBAL LICHEN NITIDUS TREATMENT MARKET, BY TREATMENT
5.1 Corticosteroids
5.2 Retinoid
5.3 Antihistamines
5.4 Others
6 GLOBAL LICHEN NITIDUS TREATMENT MARKET, BY TYPE
6.1 Topical
6.2 Oral
7 GLOBAL LICHEN NITIDUS TREATMENT MARKET, BY END USER
7.1 Hospitals
7.2 Dermatology Clinics
7.3 Others
8 GLOBAL LICHEN NITIDUS TREATMENT MARKET, BY GEOGRAPHY
8.1 Overview
8.2 North America Regional Market Estimates and Forecasts, 2012 - 2025
8.2.1 U.S.
8.2.2 Canada
8.2.3 Mexico
8.3 Europe Regional Market Estimates and Forecasts, 2012 - 2025
8.3.1 Germany
8.3.2 U.K.
8.3.3 France
8.3.4 Rest of Europe
8.4 Asia Pacific Regional Market Estimates and Forecasts, 2012 - 2025
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Rest of Asia Pacific
8.5 Latin America Regional Market Estimates and Forecasts, 2012 - 2025
8.5.1 Brazil
8.5.2 Argentina
8.6 Rest of the World Regional Market Estimates and Forecasts, 2012 â€" 2025
9 GLOBAL LICHEN NITIDUS TREATMENT MARKET COMPETITIVE LANDSCAPE
9.1 Overview
9.2 Company Market Share
9.3 Vendor Landscape
9.4 Key Development Strategies
10 COMPANY PROFILES
10.1 Pfizer Inc.
10.1.1 Overview
10.1.2 Financial Performance
10.1.3 Product Outlook
10.1.4 Key Developments
10.2 Novartis AG
10.2.1 Overview
10.2.2 Financial Performance
10.2.3 Product Outlook
10.2.4 Key Developments
10.3 Merck Sharp & Dohme Corp.
10.3.1 Overview
10.3.2 Financial Performance
10.3.3 Product Outlook
10.3.4 Key Developments
10.4 Sanofi
10.4.1 Overview
10.4.2 Financial Performance
10.4.3 Product Outlook
10.4.4 Key Developments
10.5 GlaxoSmithKline plc.
10.5.1 Overview
10.5.2 Financial Performance
10.5.3 Product Outlook
10.5.4 Key Developments
10.6 Astra Zeneca
10.6.1 Overview
10.6.2 Financial Performance
10.6.3 Product Outlook
10.6.4 Key Developments
10.7 Hubei Gedian Humanwell Pharmaceutical Co., Ltd
10.7.1 Overview
10.7.2 Financial Performance
10.7.3 Product Outlook
10.7.4 Key Developments
10.8 Farmabios SPA
10.8.1 Overview
10.8.2 Financial Performance
10.8.3 Product Outlook
10.8.4 Key Developments
10.9 Horizon Pharma plc.
10.9.1 Overview
10.9.2 Financial Performance
10.9.3 Product Outlook
10.9.4 Key Developments
11 Appendix
11.1 Related Reports